Press releases

Copenhagen, Denmark, 15 May 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the disclosure of participation by members of Curasight’s Board of Directors, Executive Management and team members in the Right Issue 2025 by exercise Curasight TO subscription rights to purchase new shares in the period May 12 - May 14, 2025.

The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) on

Wednesday 28 May 2025 at 10.00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Friday, May 16, 2025, is the last day to subscribe to Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) ongoing rights issue of shares with preferential rights for existing shareholders (the “Rights Issue”). On 4 April 2025, the Board of Directors resolved on its intention to carry out the Rights Issue. The Extraordinary General Meeting held on 23 April 2025 authorized the Board to carry out the Rights Issue, and the Board subsequently resolved to carry out the Rights Issue on 24 April 2025. Please note that certain banks and custodians may have an earlier deadline for subscription in the Rights Issue than May 16, 2025. Shareholders are therefore advised to check with their bank or custodian to confirm whether an earlier deadline applies.

Summary of the Rights Issue

· Each holder of existing shares registered with Euronext Securities as of the record date, 1 May 2025, have been allocated forty-three (43) subscription rights for each existing share held. Eighteen (18) subscription rights entitle the holder to subscribe for one (1) new share.
· The subscription price is DKK 1.98 per share, and upon full subscription, Curasight will receive approximately DKK 100 million in gross proceeds through the Rights Issue before deduction of transaction costs
· The rights issue is covered by subscription undertakings of approximately DKK 27.7 million by Curium, Pentwater, members of the Board of Directors & management and existing shareholders. In addition, the Rights issue is covered by guarantee commitments from a number of external investors, corresponding to a total of approximately DKK 19.3 million. In total, the Rights Issue is thus covered by subscription and guarantee commitments totaling approximately DKK 47 million, which corresponds to approximately 47% of the Rights Issue.

· Appointment of clinical CRO marks further step in progress in development of uTREAT as a potential new therapeutic solution for aggressive brain cancer (Glioblastoma)
· The Phase 1 trial is part of Curasight’s theranostic approach combining uTRACE and uTREAT, seeking to improve diagnosis and provide more gentle and efficient treatment of brain cancer patients

Copenhagen, May 7, 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announce it has signed a Master Service Agreement and Work Order with Premier Research, LLC, an experienced international Clinical Research Organization serving the pharmaceutical industry, to run the phase 1 trial investigating uTREAT[®] in improving the treatment of brain cancer patients.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Today is the first day of the subscription period in Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) rights issue of shares (the “Rights Issue”). On 4 April 2025, the Board of Directors resolved on its intention to carry out the Rights Issue. The Extraordinary General Meeting held on 23 April 2025 authorized the Board to carry out the Rights Issue, and the Board subsequently resolved to carry out the Rights Issue on 24 April 2025.

Copenhagen, Denmark, 30 April 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO professor Andreas Kjær will present the Right Issue of new shares and the company’s latest progress at HC Andersen Capital

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) publishes a disclosure document relating to the rights issue of shares of approximately DKK 100 million before deduction of issue costs (the “Rights Issue”). On 4 April 2025, the Board of Directors resolved on its intention to carry out the Rights Issue. The Extraordinary General Meeting held on 23 April 2025 authorized the Board to carry out the Rights Issue, and the Board subsequently resolved to carry out the Rights Issue on 24 April 2025.

Copenhagen, Denmark, 25 April 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the fiscal year of 2024. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Copenhagen, Denmark, 25 April 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report Q1 2025. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

On 4 April 2025, the Board of Directors of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) resolved on its intention to carry out a rights issue of shares, with pre-emption rights for the Company’s existing shareholders (the “Rights Issue”). Following the extraordinary general meeting on 23 April 2025 (the “EGM”), the Board of Directors has today based on the authorization granted by the EGM, formally resolved to carry out the Rights Issue and its final terms. If the Rights Issue is fully subscribed, the Company will receive approximately DKK 100 million before issue related costs. The Company has received pre-subscription commitments of approximately DKK 27.7 million and guarantee commitments of approximately DKK 19.3 million. Together, these commitments cover approximately 47 percent of the maximum amount in the Rights Issue. Curium International Trading B.V. ("Curium") has expressed its strong support for the Rights Issue and has committed to subscribe for a total of DKK 17.8 million. Additionally, the institutional investor Pentwater Capital Management Europe LLP (“Pentwater”) has committed to subscribe for 10 percent of the final issue volume, with a minimum investment of approximately DKK 4.7 million. Curasight's management, members of the Board of Directors, and existing shareholders have committed to subscribe for a combined total of approximately DKK 5.2 million.